Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.

Suppr

超能文献

作者信息

Radice P A, Bunn P A, Ihde D C

出版信息

Cancer Treat Rep. 1979 Aug;63(8):1231-9.

PMID:225026

Abstract

摘要

相似文献

Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.

Cancer Treat Rep. 1979 Aug;63(8):1231-9.

Etoposide (VP-16-213). Current status of an active anticancer drug.依托泊苷（VP - 16 - 213）。一种活性抗癌药物的现状。

N Engl J Med. 1985 Mar 14;312(11):692-700. doi: 10.1056/NEJM198503143121106.

Treatment strategies in relation to drug action.与药物作用相关的治疗策略。

NCI Monogr. 1987(4):129-33.

[New antineoplastic drugs of the podophyllotoxin derivative group].[鬼臼毒素衍生物类新型抗肿瘤药物]

Pol Tyg Lek. 1983 Jan 3;38(1):27-30.

[Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies].

Gan To Kagaku Ryoho. 1986 Mar;13(3 Pt 1):496-501.

[Phase II study of etoposide (NK 171) in advanced hematological malignancies].

Gan To Kagaku Ryoho. 1984 Aug;11(8):1579-84.

Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.

Cancer Treat Rep. 1977 May-Jun;61(3):489-90.

[A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung].

Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 1):931-7.

Multicenter Phase II trial of etoposide in refractory small cell lung cancer.

Cancer Treat Rep. 1985 Jan;69(1):127-8.

[A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].

Gan To Kagaku Ryoho. 1986 Jan;13(1):116-21.

引用本文的文献

Targeting EMT using low-dose Teniposide by downregulating ZEB2-driven activation of RNA polymerase I in breast cancer.通过下调 ZEB2 驱动的 RNA 聚合酶 I 激活来低剂量依托泊苷靶向 EMT 治疗乳腺癌。

Cell Death Dis. 2024 May 8;15(5):322. doi: 10.1038/s41419-024-06694-7.

Overcoming multiple drug resistance mechanisms in medulloblastoma.克服髓母细胞瘤中的多种耐药机制。

Acta Neuropathol Commun. 2014 May 30;2:57. doi: 10.1186/2051-5960-2-57.

Primary WWOX phosphorylation and JNK activation during etoposide induces cytotoxicity in HEK293 cells.依托泊苷诱导 HEK293 细胞毒性过程中 WW0X 的初步磷酸化和 JNK 的激活。

Daru. 2010;18(2):141-5.

Inhibition of CYP3A4 and CYP2C9 by podophyllotoxin: implication for clinical drug-drug interactions.鬼臼毒素对 CYP3A4 和 CYP2C9 的抑制作用：对临床药物相互作用的影响。

J Biosci. 2011 Dec;36(5):879-85. doi: 10.1007/s12038-011-9143-9.

Pharmacokinetic optimisation of treatment with oral etoposide.口服依托泊苷治疗的药代动力学优化

Clin Pharmacokinet. 2004;43(7):441-66. doi: 10.2165/00003088-200443070-00002.

Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group.顺铂和依托泊苷用于食管癌治疗：一项II期研究。鹿特丹食管癌研究组

Br J Cancer. 1996 Sep;74(6):980-4. doi: 10.1038/bjc.1996.469.

Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer.21天口服依托泊苷治疗肺癌的治疗药物监测

Jpn J Cancer Res. 1996 Aug;87(8):856-61. doi: 10.1111/j.1349-7006.1996.tb02111.x.

Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.依托泊苷（VP16）长期口服治疗复发性恶性胶质瘤患者的II期研究。

J Neurooncol. 1996 Feb;27(2):149-55. doi: 10.1007/BF00177478.

Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer.依托泊苷在非小细胞肺癌14天输注治疗中的治疗药物监测

Jpn J Cancer Res. 1996 Feb;87(2):200-5. doi: 10.1111/j.1349-7006.1996.tb03159.x.

Cytotoxic properties of a new synthetic demethylpodophyllotoxin derivative, BN 58705, against human tumor cell lines.一种新型合成去甲基鬼臼毒素衍生物BN 58705对人肿瘤细胞系的细胞毒性特性

Cancer Chemother Pharmacol. 1993;32(4):293-300. doi: 10.1007/BF00686175.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验